Once daily fixed dose inhaler of steroids and LABA effective in asthma, finds study

Once daily Fixed Dose Combination (FDC) of Inhaled Corticosteroid (ICS) and Long Acting Beta-Agonists (LABA) are safe and significantly improved lung function in asthmatic patients, found a recent study. The study was published in the journal, 'The Lancet, Respiratory Medicine' 2020.
Researchers across 24 countries conducted a trial from over 316 centres to assess the efficacy and safety of once-daily FDC of mometasone furoate plus indacaterol acetate (MF–IND) versus mometasone furoate (MF) monotherapy in patients with inadequately controlled asthma. The trial was conducted on patients aged 12 to 75yrs from Dec 29, 2015, to May 4, 2018. Inclusion criteria were those who had a documented diagnosis of asthma for at least 1 year, a predicted FEV1 of 50–85%, and an Asthma Control Questionnaire 7 score of at least 1·5. Patients who were under treatment with medium-dose or high-dose ICS or low-dose ICS plus LABA were also included.
Based on these the selected patients were randomly assigned (1:1:1:1:1) via interactive response technology to receive one of the following treatments for 52 weeks. They were under high-dose MF–IND (320 μg, 150 μg) or medium-dose MF–IND (160 μg, 150 μg) once daily via Breezhaler; high-dose MF (800 μg [400 μg twice daily]) or medium-dose MF (400 μg once daily) via Twisthaler; or high-dose fluticasone propionate–salmeterol xinafoate (FLU–SAL; 500 μg, 50 μg) twice daily via Diskus. Participants received placebo via inhalation through the Breezhaler, Twisthaler, or Diskus devices in the mornings and evenings, as appropriate. Improvement in trough FEV1 from baseline at 26 weeks was the primary endpoint.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.